Strength Seen in Viridian Therapeutics (VRDN): Can Its 8.7% Jump Turn into More Strength?

The sudden soaring of the stock price can be attributed to positive investor mindset regarding the progress of Viridian's clinical-stage pipeline. The company is evaluating its lead candidate, VRDN-001 in active and chronic thyroid eye disease (TED) in two separate late-stage studies, namely THRIVE and THRIVE-2, respectively. While top-line data from the THRIVE study is expected in September, data from the THRIVE-2 study is anticipated before this year's end. If the outcomes from both studies are positive, ...